Developer docs
API playgroundTry for free, no card

Search company profiles

Delphinus Medical Technologies

Full company profile

uuid00024ef

Namestring
Delphinus Medical Technologies
Legal namestring
Delphinus Medical Technologies, Inc.
Websiteurl
delphinusmt.com
Company typeenum
Private
Founded yearint
2010
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersNovi, United States
HQ citystring
Novi
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
breast ultrasound tomography, dense breast screening, medical imaging devices, radiology equipment, breast cancer detection
Industry3 codes
PRIMARYHLAHABAF
Mammography & Breast Imaging Systems
Healthcare & Life Sciences/Medical Devices & Diagnostics/Medical Imaging & Radiology Equipment
SECONDARYHLAFAKAD
Breast Imaging Centers (Mammography/Tomosynthesis)
SECONDARYHLAFAJAJ
Women’s Imaging & Breast Health Centers
Healthcare & Life Sciences/Healthcare Providers & Systems/Women’s & Children’s Health Providers
NAICS code1 code
  • Surgical and Medical Instrument Manufacturing339112
SIC code1 code
  • Surgical & Medical Instruments & Apparatus3841
Product category
Breast Imaging Systems
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1SoftVue System Sales
TypeHardware Sales
Description

Sale of SoftVue 3D Whole Breast Ultrasound Tomography medical imaging systems to hospitals, breast imaging centers, and healthcare facilities. The system is sold as capital equipment with associated consumables (Sequr Breast Interface pads). Revenue recognized upon system installation and acceptance.

delphinusmt.com
2Medical Device Billing (CPT 76641)
TypeOne Time License
Description

SoftVue procedures are billed under existing insurance code CPT 76641 for whole breast ultrasound. Healthcare providers purchase/lease the equipment and generate revenue through insurance reimbursement for screening procedures performed on patients.

delphinusmt.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1SoftVue™
Description

FDA-approved 3D Whole Breast Ultrasound Tomography System for screening women with dense breasts as adjunct to digital mammography. Features proprietary TriAD technology with 360-degree ring transducer.

delphinusmt.com
+2 more records
Core offering1 text field

Delphinus Medical Technologies develops, manufactures, and commercializes the SoftVue 3D Whole Breast Ultrasound Tomography System, an FDA PMA-approved imaging device used as an adjunct to mammography for screening women with dense breast tissue. The system is sold as capital equipment to hospitals and breast imaging centers, along with disposable Sequr Breast Interface consumables used during each scan.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Identifies up to 20-25% more cancers when combined with mammography
+4 more records
Product overview1 text field

Delphinus Medical Technologies offers a single core product platform—the SoftVue 3D Whole Breast Ultrasound Tomography System—designed specifically for dense breast cancer screening. The FDA-approved system uses proprietary TriAD (Triple Acoustic Detection) technology with a 360-degree ring transducer containing over 2,000 elements. When combined with standard mammography, SoftVue identifies up to 20-25% more cancers with greater accuracy. The system requires no radiation or breast compression and is approved for same-day screening alongside mammography. A配套 consumable, the Sequr Breast Interface, is used during each scan procedure.

Product and service2 records
1SoftVue 3D Whole Breast Ultrasound Tomography System
CategoryBreast Imaging Systems
Description

FDA PMA-approved 3D whole breast ultrasound tomography system using proprietary TriAD (Triple Acoustic Detection) technology with a 360-degree ring transducer containing over 2,000 elements to capture reflection, sound speed, and attenuation signals. Indicated as an adjunct to digital mammography for screening asymptomatic women with dense breast tissue. Requires no radiation or breast compression and is approved for same-day screening alongside mammography.

2Sequr Breast Interface
Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2024-08-13
Description

Delphinus awarded national group purchasing agreement and Technology Breakthrough designation from Premier. SoftVue is now listed as a top supplier for Premier's members, who can access special pricing and terms pre-negotiated by Premier. Premier is a leading healthcare improvement company uniting approximately 4,350 U.S. hospitals and 300,000 other providers. SoftVue was featured at Premier's Breakthroughs24 annual conference as one of the 'latest and greatest' technologies.

2Karmanos Cancer Institute
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Original research institution where SoftVue technology was conceived and developed. Delphinus was founded as a spin-out of Karmanos in 2010. Karmanos was the first customer to purchase and install SoftVue.

delphinusmt.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Supported clinical study comparing whole breast ultrasound tomography and mammography for breast cancer risk assessment through a contract. Study conducted by researchers from NCI, Karmanos Cancer Institute, Wayne State University, Henry Ford Health Systems, Mayo Clinic, and George Washington University.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Dominant player in breast imaging with the Selenia Dimensions mammography platform and 3Dimensions systems. Directly comparable as the leading supplier of breast cancer screening equipment to the same hospital and imaging center customer base, and competes with SoftVue as the incumbent mammography modality.

TypeBroad incumbent
Description

Mammography OEM with the MAMMOMAT platform and broader breast imaging portfolio including ultrasound and MRI. Competes for the same capital equipment budget at hospitals and breast imaging centers.

TypeBroad incumbent
Description

Provides the Aspire Cristalle mammography system and breast imaging solutions to hospitals and imaging centers. Competes directly for breast imaging capital equipment purchases.

TypeBroad incumbent
Description

Major medical imaging OEM with mammography, ultrasound, and MRI breast imaging offerings, including dedicated breast MRI systems. Competes for hospital breast imaging capital budget and serves the same screening and diagnostic workflows.

TypeEmerging player
Description

Developed the Imagio optoacoustic/ultrasound breast imaging system for diagnostic breast imaging. Comparable as a novel breast imaging modality targeting improved characterization of breast lesions, particularly in dense tissue.

TypeEmerging player
Description

Provides AI-powered breast imaging software (Transpara) for mammography triage and decision support, including for dense-breast cases. Adjacent competitor helping radiologists interpret mammograms more effectively in dense tissue.

TypeBroad incumbent
Description

Large incumbent with Senographe mammography systems and the Invenia Automated Breast Ultrasound (ABUS) system, which is a primary competing modality for dense-breast supplemental screening. Targets the same hospital and breast imaging center buyers.

TypeDirect peer
Description

Provides AI-based breast cancer detection and risk assessment software (ProFound AI) used alongside mammography, including for dense-breast assessment. Comparable in addressing the dense-breast screening workflow with a different technology approach (AI on mammograms vs. ultrasound tomography).

TypeEmerging player
Description

Developer of a no-radiation, no-compression breast imaging system using ultrasound tomography. Most direct technological peer to SoftVue as a competing radiation-free breast imaging modality with similar patient experience positioning.

TypeDirect peer
Description

Provides breast density assessment and risk evaluation software integrated into mammography workflows. Targets the same dense-breast screening use case with a complementary software-based approach to identifying patients who need supplemental screening.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors9 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Delphinus Medical Technologies

Breast Imaging Systemsdelphinusmt.com

Delphinus Medical Technologies firmographics

Firmographics
Name
Delphinus Medical Technologies
Legal name
Delphinus Medical Technologies, Inc.
Website
https://delphinusmt.com
Company type
Private
Founded year
2010
Operating status
Operating
Headcount range
51–100 employees
Ownership category
akta.pro rank

Delphinus Medical Technologies industry classification

Industry
Product category
Breast Imaging Systems
NAICS
Surgical and Medical Instrument Manufacturing (339112)
SIC
Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAHABAF
Mammography & Breast Imaging Systems
Healthcare & Life Sciences/Medical Devices & Diagnostics/Medical Imaging & Radiology Equipment
SECONDARYHLAFAKAD
Breast Imaging Centers (Mammography/Tomosynthesis)
SECONDARYHLAFAJAJ
Women’s Imaging & Breast Health Centers
Healthcare & Life Sciences/Healthcare Providers & Systems/Women’s & Children’s Health Providers

Keywords

  • Breast ultrasound tomography
  • Dense breast screening
  • Medical imaging devices
  • Radiology equipment
  • Breast cancer detection

Where Delphinus Medical Technologies is headquartered

Location

Headquarters

HQ city
Novi
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Delphinus Medical Technologies business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations

Revenue model

  1. SoftVue System Sales: Sale of SoftVue 3D Whole Breast Ultrasound Tomography medical imaging systems to hospitals, breast imaging centers, and healthcare facilities. The system is sold as capital equipment with associated consumables (Sequr Breast Interface pads). Revenue recognized upon system installation and acceptance.
  2. Medical Device Billing (CPT 76641): SoftVue procedures are billed under existing insurance code CPT 76641 for whole breast ultrasound. Healthcare providers purchase/lease the equipment and generate revenue through insurance reimbursement for screening procedures performed on patients.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels7 records

Delphinus Medical Technologies product offering

Product offering

Core offering

Delphinus Medical Technologies develops, manufactures, and commercializes the SoftVue 3D Whole Breast Ultrasound Tomography System, an FDA PMA-approved imaging device used as an adjunct to mammography for screening women with dense breast tissue. The system is sold as capital equipment to hospitals and breast imaging centers, along with disposable Sequr Breast Interface consumables used during each scan.

Product overview

Delphinus Medical Technologies offers a single core product platform—the SoftVue 3D Whole Breast Ultrasound Tomography System—designed specifically for dense breast cancer screening. The FDA-approved system uses proprietary TriAD (Triple Acoustic Detection) technology with a 360-degree ring transducer containing over 2,000 elements. When combined with standard mammography, SoftVue identifies up to 20-25% more cancers with greater accuracy. The system requires no radiation or breast compression and is approved for same-day screening alongside mammography. A配套 consumable, the Sequr Breast Interface, is used during each scan procedure.

Differentiator

Problem solved

Functional benefit

Brands

  • SoftVue™: FDA-approved 3D Whole Breast Ultrasound Tomography System for screening women with dense breasts as adjunct to digital mammography. Features proprietary TriAD technology with 360-degree ring transducer.
  • TriAD™
  • Sequr™ Breast Interface

Products and services

  • SoftVue 3D Whole Breast Ultrasound Tomography System FDA PMA-approved 3D whole breast ultrasound tomography system using proprietary TriAD (Triple Acoustic Detection) technology with a 360-degree ring transducer containing over 2,000 elements to capture reflection, sound speed, and attenuation signals. Indicated as an adjunct to digital mammography for screening asymptomatic women with dense breast tissue. Requires no radiation or breast compression and is approved for same-day screening alongside mammography.
  • Sequr Breast Interface

Quantifiable outcome

  • Identifies up to 20-25% more cancers when combined with mammography
  • +4 more outcomes

Companies that use Delphinus Medical Technologies

Customer profile

Named customers4 records

Segments3 records

Ideal customer profiles2 records

Delphinus Medical Technologies technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Delphinus Medical Technologies partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core.

  • Premier, Inc.coreChannel Partner/ Reseller/ Distributor · 13 August 2024Delphinus awarded national group purchasing agreement and Technology Breakthrough designation from Premier. SoftVue is now listed as a top supplier for Premier's members, who can access special pricing and terms pre-negotiated by Premier. Premier is a leading healthcare improvement company uniting approximately 4,350 U.S. hospitals and 300,000 other providers. SoftVue was featured at Premier's Breakthroughs24 annual conference as one of the 'latest and greatest' technologies.
  • Karmanos Cancer InstitutecoreStrategic or Co-development PartnerOriginal research institution where SoftVue technology was conceived and developed. Delphinus was founded as a spin-out of Karmanos in 2010. Karmanos was the first customer to purchase and install SoftVue.
  • National Cancer Institute (NIH)coreStrategic or Co-development PartnerSupported clinical study comparing whole breast ultrasound tomography and mammography for breast cancer risk assessment through a contract. Study conducted by researchers from NCI, Karmanos Cancer Institute, Wayne State University, Henry Ford Health Systems, Mayo Clinic, and George Washington University.

Scale indicators7 records

Recent moves7 records

Expansion highlights5 records

Delphinus Medical Technologies competitors and assessment

Company assessment

Broad incumbents

  • Hologic: Dominant player in breast imaging with the Selenia Dimensions mammography platform and 3Dimensions systems. Directly comparable as the leading supplier of breast cancer screening equipment to the same hospital and imaging center customer base, and competes with SoftVue as the incumbent mammography modality.
  • Siemens Healthineers: Mammography OEM with the MAMMOMAT platform and broader breast imaging portfolio including ultrasound and MRI. Competes for the same capital equipment budget at hospitals and breast imaging centers.
  • Fujifilm Healthcare: Provides the Aspire Cristalle mammography system and breast imaging solutions to hospitals and imaging centers. Competes directly for breast imaging capital equipment purchases.
  • Koninklijke Philips: Major medical imaging OEM with mammography, ultrasound, and MRI breast imaging offerings, including dedicated breast MRI systems. Competes for hospital breast imaging capital budget and serves the same screening and diagnostic workflows.
  • GE HealthCare: Large incumbent with Senographe mammography systems and the Invenia Automated Breast Ultrasound (ABUS) system, which is a primary competing modality for dense-breast supplemental screening. Targets the same hospital and breast imaging center buyers.

Emerging players

  • Seno Medical Instruments: Developed the Imagio optoacoustic/ultrasound breast imaging system for diagnostic breast imaging. Comparable as a novel breast imaging modality targeting improved characterization of breast lesions, particularly in dense tissue.
  • ScreenPoint Medical: Provides AI-powered breast imaging software (Transpara) for mammography triage and decision support, including for dense-breast cases. Adjacent competitor helping radiologists interpret mammograms more effectively in dense tissue.
  • QT Imaging: Developer of a no-radiation, no-compression breast imaging system using ultrasound tomography. Most direct technological peer to SoftVue as a competing radiation-free breast imaging modality with similar patient experience positioning.

Direct peers

  • iCAD: Provides AI-based breast cancer detection and risk assessment software (ProFound AI) used alongside mammography, including for dense-breast assessment. Comparable in addressing the dense-breast screening workflow with a different technology approach (AI on mammograms vs. ultrasound tomography).
  • Volpara Health: Provides breast density assessment and risk evaluation software integrated into mammography workflows. Targets the same dense-breast screening use case with a complementary software-based approach to identifying patients who need supplemental screening.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

Delphinus Medical Technologies social profiles

Digital presence

Delphinus Medical Technologies compliance and trust

Trust signal

Compliance2 records

Delphinus Medical Technologies financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Delphinus Medical Technologies leadership team

Management profile

Number of profiles

Profiles8 records

Delphinus Medical Technologies funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Delphinus Medical Technologies M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Delphinus Medical Technologies

What does Delphinus Medical Technologies do?

Delphinus Medical Technologies develops, manufactures, and commercializes the SoftVue 3D Whole Breast Ultrasound Tomography System, an FDA PMA-approved imaging device used as an adjunct to mammography for screening women with dense breast tissue. The system is sold as capital equipment to hospitals and breast imaging centers, along with disposable Sequr Breast Interface consumables used during each scan.

Is Delphinus Medical Technologies a public or private company?

Delphinus Medical Technologies is a private company. It is classified as venture growth investor backed and is currently operating.

When was Delphinus Medical Technologies founded?

Delphinus Medical Technologies was founded in 2010. It employs 51 to 100 people.

Where is Delphinus Medical Technologies based?

Delphinus Medical Technologies is headquartered in Novi, United States, in the North America region.

How does Delphinus Medical Technologies make money?

Two revenue lines are on record. SoftVue System Sales are the primary driver. The others are medical Device Billing (CPT 76641).

Who are Delphinus Medical Technologies's main competitors?

Broad incumbents on record are Hologic, Siemens Healthineers, Fujifilm Healthcare, Koninklijke Philips and GE HealthCare. Emerging players are Seno Medical Instruments, ScreenPoint Medical and QT Imaging. Direct peers are iCAD and Volpara Health.

Does Delphinus Medical Technologies have an API?

No public API is recorded for Delphinus Medical Technologies.

What industry is Delphinus Medical Technologies in?

Delphinus Medical Technologies's product category is Breast Imaging Systems. Its primary akta.pro industry code is HLAHABAF, Mammography & Breast Imaging Systems, with a secondary code of HLAFAKAD, Breast Imaging Centers (Mammography/Tomosynthesis). Its NAICS code is 339112 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Medical Device and Diagnostic industryDelphinus Wants to Transform Dense Breast ScreeningDelphinus Medical Technologies raised $30 million in a Series D funding round to support the commercialization of its SoftVue 3D whole breast ultrasound tomography system. The company recently secured PMA approval for dense breast screening and sold its first unit to Karmanos Cancer Institute, aiming to enhance cancer detection rates compared to standard mammography.Mpo-magGE Loans $6 Million to DelphinusGE Healthcare Financial Services has granted a $6 million multi-draw loan to Delphinus Medical Inc. for clinical and early commercialization efforts. The funding supports Delphinus's development of its SoftVue breast tomography system, which is currently awaiting FDA clearance.GlobeNewswireDELPHINUS MEDICAL TECHNOLOGIES AND AUSTIN RADIOLOGICAL ASSOCIATION MARK MILESTONE IN ADVANCED SCREENING FOR WOMEN WITH DENSE BREASTSAustin Radiological Association launched SoftVue, an FDA-approved breast ultrasound tomography system, at its Cedar Park location in December. The system finds 25% more cancers than mammography alone in women with dense breasts, which affects up to 40% of U.S. women. Delphinus Medical Technologies and ARA announced the milestone.GlobeNewswireDELPHINUS MEDICAL TECHNOLOGIES AND AUSTIN RADIOLOGICAL ASSOCIATION MARK MILESTONE IN ADVANCED SCREENING FOR WOMEN WITH DENSE BREASTSAustin Radiological Association launched SoftVue, an FDA-approved breast ultrasound tomography system, at its Cedar Park location in December. The system finds 25% more cancers than mammography alone in women with dense breasts, requiring no compression or radiation. The collaboration aims to expand access to early detection for this high-risk group.YahooDELPHINUS MEDICAL TECHNOLOGIES AND AUSTIN RADIOLOGICAL ASSOCIATION MARK MILESTONE IN ADVANCED SCREENING FOR WOMEN WITH DENSE BREASTSAustin Radiological Association launched a SoftVue screening program in December at its Cedar Park location, using FDA-approved ultrasound tomography for dense breast tissue. The technology finds 25% more cancers than mammography alone and requires no compression or radiation. The collaboration aims to expand access and improve patient compliance.YahooDelphinus Medical Technologies Awarded Technology Breakthrough From Premier, Inc.Delphinus Medical Technologies received a national group purchasing agreement and Technology Breakthrough designation from Premier for its SoftVue breast ultrasound tomography system. The FDA-approved system shows up to 25% more cancer detection in dense breasts and reduces call-backs. Premier's alliance includes about 4,350 U.S. hospitals and 300,000 providers.Business Wire BlogDelphinus Medical Technologies Awarded Technology Breakthrough From Premier, Inc.Delphinus Medical Technologies received a national group purchasing agreement and Technology Breakthrough designation from Premier, Inc. for its SoftVue Breast Ultrasound Tomography system. This recognition allows Premier’s member hospitals to access special pricing and terms for the device, which is designed to improve cancer detection in women with dense breasts.Imaging Technology NewsStudy Demonstrates Superiority of Ultrasound Tomography System in Conjunction with Mammography for Breast Cancer Screening in Women with Dense BreastsDelphinus Medical Technologies announced a study published in the journal Radiology demonstrating that its SoftVue Breast Ultrasound Tomography system, when used alongside mammography, significantly improves breast cancer detection rates in women with dense breasts. The multi-reader study showed a 25% increase in sensitivity for BI-RADS 4 or higher lesions and an 8% improvement in specificity for BI-RADS 3 lesions compared to mammography alone. This development offers a new screening solution aligned with upcoming U.S. federal mandates for breast density notifications.Medical Device NetworkDelphinus’ SoftVue outshines mammography alone in cancer detectionA study published in the journal Radiology indicates that Delphinus Medical Technology’s SoftVue ultrasound tomography system significantly improves breast cancer detection rates when used alongside mammography for women with dense breasts. The integration of SoftVue increased sensitivity for detecting BI-RADS 4 or higher lesions by 25% and improved specificity for BI-RADS 3 lesions by 8% compared to mammography alone. This technology, which received FDA premarket approval in October 2021, offers a radiation-free alternative utilizing sound and water to image the entire breast.DBusiness MagazineDelphinus Medical Technologies in Novi Names Rama Gundlapalli Vice President of EngineeringDelphinus Medical Technologies Inc. has appointed Rama Gundlapalli as its new vice president of engineering, effective immediately. Gundlapalli brings over 30 years of experience in product development and engineering, previously serving as senior director of research collaborations at Siemens Healthineers. This leadership addition aims to advance the company's SoftVue technology for breast cancer detection.